Hemorrhagic cystitis is a major cause of morbidity after bone marrow transplantation. Traditional methods of prevention have included mesna (2-mercaptoethane sodium sulfonate) and bladder irrigation. We report the use of hyperhydration as an alternative to these prophylactic measures. One hundred consecutive patients who underwent autologous or allogeneic bone marrow transplantation received high dose cyclophosphamide with hyperhydration using 5% dextrose normal saline at the rate of 250 ml/h and furosemide to maintain a urine output of >150 ml/h. Seventy-one of these patients also received high dose cyclophosphamide as mobilization chemotherapy. There were no episodes of hemorrhagic cystitis following mobilization chemotherapy. The incidence of hemorrhagic cystitis after transplant conditioning was 7% with 2 patients developing clinically significant hemorrhagic cystitis; one was a severe episode. The cost of hyperhydration was US$ 20 per course as opposed to US$ 1,500 per course for mesna, based on acquisition costs at our institution. We conclude that hyperhydration is a safe, inexpensive means of preventing hemorrhagic cystitis associated with high dose cyclophosphamide in bone marrow transplant recipients.

1.
Welch HG, Larson EB: Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 1989;321:807–812.
2.
Bezwoda WR, Seymour L, Dansey R: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 1995;13:2483–2489.
3.
Jourdan E, Maraninchi D, Reiffers J, Gluckman E, Rio B, Jouet JP, Michallet M, Molina L, Archimbaud E, Harousseau JL, Ifrah N, Attal M, Guilhot F, Kuentz M, Guyotat D, Pico JL, Dauriac C, Legros M, Dreyfus F, Bordingoni P, Leblond V, Gratecos N, Varet B, Auzanneau C, Tilly H, Vilmer E, Bardou VJ, Blaise D for the Société Française de Greffe de Moelle (SFGM): Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Bone Marrow Transplant 1997;19:875–881.
4.
Nadermanee A, Molina A, O’Donnell MR, Dagis A, Snyder DS, Parker P, Stein A, Smith E, Planans I, Kashyap A, Spielberger R, Fung H, Wong KK, Somlo G, Mangolin K, Chow W, Sniecinski I, Vora N, Blume K, Niland J, Forman SJ: Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate and high-grade lymphoma: International index high and high-intermediate risk group. Blood 1997;90:3844–3852.
5.
Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelev L, Parkkali T, Lenhoff S, Sallerfors B, Ljungman P, Mellander L, Jacobsen N: A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recepients with leukemia: A report for the Nordic Bone Marrow Transplantation Group. Blood 1994;83:2723–2730.
6.
Vose JN, Reed EC, Pippert GC, Anderson JR, Pierman PJ, Kessinger A, Spinolo J, Armitage JO: Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: A randomized trial. J Clin Oncol 1993;11:1306–1310.
7.
Phillips FS, Sternberg SS, Cronin AP: Cyclophosphamide and urinary bladder toxicity. Cancer Res 1961;21:1577–1589.
8.
Miller LJ, Chandler SW, Ippoliti CM: Treatment of cyclophosphamide-induced hemorrhagic cystitis with prostaglandins. Ann Pharmacother 1994;28:590–594.
9.
Efros MD, Ahmed T, Coombe N, Choudhury MS: Urologic complications of high-dose chemotherapy and bone marrow transplantation. Urology 1993;43:355–360.
10.
Sencer SF, Haake RJ, Weisdorf DJ: Hemorrhagic cystitis after bone marrow transplantation. Transplantation 1993;56:875–879.
11.
Yang CC, Hurd DD, Case LD, Assimos DG: Hemorrhagic cystitis in bone marrow transplantation. Urology 1994;44:322–327.
12.
Morgan M, Dodds A, Atkinson K, Szer J, Downs K, Biggs J: The toxicity of busulfan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol 1991;77:529–534.
13.
Knudsen LM, Gaarsdal E, Jensen L, Nielsen K, Nikolaisen K, Johnsen HE: Improved priming for mobilization of an optimal timing for harvest of peripheral blood stem cells. J Hematother 1996;5:399.
14.
Watts MJ, Sullivan AM, Jamieson E, Pearce R, Fielding A, Devereaux S, Goldstone AH, Linch DC: Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: An analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997;15:535.
15.
Damier R, Buckner CD, Storer B, Lileby K, Rowley S, Clift R, Appelbaum FR, Storb R, Bensinger WI: Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. J Clin Oncol 1997;15:684.
16.
Turkeri LN, Lum LG, Uberti JP, Abella E, Momin F, Karanes C, Sensenbrenner LL, Haas GP: Prevention of hemorrhagic cystitis following allogeneic bone marrow transplant preparative regimens with cyclophosphamide and busulfan: Role of continuous bladder irrigation. J Urol 1995;153:637–640.
17.
Haselberg MB, Schwinghammer TL: Efficacy of mesna for preventive of hemorrhagic cystitis after high-dose cyclophosphamide therapy. Ann Pharmacother 1995;29:918–920.
18.
Schulman KA, Birch R, Zhen B, Pania N, Weaver CH: Effect of CD 34+ cell dose of resource utilization in patients after high-dose chemotherapy with peripheral-blood stem cell support. J Clin Oncol 1999;17:1227–1233.
19.
Demirer T, Buckner CD, Storer B, Lilleby K, Rowley S, Clift R, Applebaum FR, Storb R, Bensinger WI: Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. J Clin Oncol 1997;15:684–690.
20.
Hartman AR, Williams SF, Dillon JJ: Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: A meta-analysis. Bone Marrow Transplant 1998;22:439–443.
21.
Haioun C, Lepage E, Gisselbrecht C, Bastian Y, Coiffier B, Brice P, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Briere J, Gaulard P, Reyes F: Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: Updated results of the prospective study LNH 87-2. J Clin Oncol 1997;15:1131–1137.
22.
Shepard JD, Pringle LE, Barnett MJ, Klingermann H-G, Reece DE, Phillips GL: Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 1991;9:2016–2020.
23.
Meisenberg B, Lassiter M, Hussein A, Ross M, Vredenburgh JJ, Peters WP: Prevention of hemorrhagic cystitis after high-dose alkylating agent chemotherapy and autologous bone marrow support. Bone Marrow Transplant 1994;14:287–291.
24.
Letendre L, Hoagland HC, Gertz MA: Hemorrhagic cystitis complicating bone marrow transplantation. Mayo Clin Proc 1992;67:128–130.
25.
Trotman T, Nivison-Smith I, Dodds A: Haemorrhagic cystitis: Incidence and risk factors in a transplant population using hyperhydration. Bone Marrow Transplant 1999;23:797–801.
26.
Nicolau DP, Hogan KR: National survey of use of mesna for the prevention of cyclophosphamide-induced hemorrhagic cystitis in recipients of bone marrow transplants (letter). Mayo Clin Proc 1992;67:612–613.
27.
Arthur RR, Shah KV, Baust SJ, Santos GW, Saral R: Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplants. N Engl J Med 1986;315:230–234.
28.
Bedi A, Miller CB, Hanson JL, Goodman S, Ambinder RF, Charache P, Arthur RR, Jones RJ: Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol 1995;13:1103–1109.
29.
Spach DH, Bauwens JE, Myerson D, Mustafa MM, Bowden RA: Cytomegalovirus-induced hemorrhagic cystitis following bone marrow transplantation. Clin Infect Dis 1993;16:142–144.
30.
Murphy GF, Wood DP Jr, McRoberts JW, Henslee-Downey JP: Adenovirus-associated hemorrhagic cystitis treated with intravenous ribavirin. J Urol 1993;49:565–566.
31.
Apperley JF, Rice SJ, Bishop JA, Chia YC, Krausz T, Gardner SD, Goldman JM: Late-onset hemorrhagic cystitis associated with urinary excretion of polyomaviruses after bone marrow transplantation. Transplantation 1987;43:108–112.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.